Modality
Multispecific
MOA
FcRni
Target
FcRn
Pathway
Apoptosis
CRCMS
Development Pipeline
Preclinical
Apr 2018
→ May 2026
PreclinicalCurrent
NCT07404532
1,817 pts·MS
2018-04→2026-05·Completed
1,817 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-212mo awayInterim· MS
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Complet…
Catalysts
Interim
2026-05-21 · 2mo away
MS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07404532 | Preclinical | MS | Completed | 1817 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |